CAS 220347-05-7
:(1S,2R,3S,4R)-4-(7-(((1R,2S)-2-(3,4-difluorophenyl)cyclopropyl)amino)-5-(propylthio)-3H-[1,2,3]triazolo[4,5-d]pyrimidin-3-yl)cyclopentane-1,2,3-triol
Description:
The chemical substance with the name "(1S,2R,3S,4R)-4-(7-(((1R,2S)-2-(3,4-difluorophenyl)cyclopropyl)amino)-5-(propylthio)-3H-[1,2,3]triazolo[4,5-d]pyrimidin-3-yl)cyclopentane-1,2,3-triol" and CAS number "220347-05-7" is a complex organic compound characterized by its multi-cyclic structure and specific stereochemistry. It features a cyclopentane core substituted with a triazolopyrimidine moiety, which is linked to a cyclopropyl group containing a difluorophenyl substituent. The presence of multiple functional groups, including amino and thiol groups, suggests potential biological activity, possibly as a pharmaceutical agent. The stereochemical configuration indicated by the (1S,2R,3S,4R) and (1R,2S) descriptors implies that the compound exhibits chirality, which can significantly influence its interaction with biological targets. This compound may be investigated for its pharmacological properties, including its efficacy and safety profile in various therapeutic applications. Overall, its intricate structure and functional diversity make it a subject of interest in medicinal chemistry and drug development.
Sort by
Purity (%)
0
100
|
0
|
50
|
90
|
95
|
100
Found 11 products.
O-Dealkyl Ticagrelor ((1S,2R,3S,4R)-4-(7-(((1R,2S)-2-(3,4-difluorophenyl)cyclopropyl)amino)-5-(propylthio)-3H-[1,2,3]triazolo[4,5-d]pyrimidin-3-yl)cyclopentane-1,2,3-triol)
CAS:Compounds containing a pyrimidine ring, whether or not hydrogenated, or piperazine ring in the structure, nesoiFormula:C21H24F2N6O3SColor and Shape:White PowderMolecular weight:478.15987Deshydroxyethoxy Ticagrelor
CAS:Formula:C21H24F2N6O3SColor and Shape:Off-White SolidMolecular weight:478.52Deshydroxyethoxy Ticagrelor-d7
CAS:Formula:C21H17D7F2N6O3SColor and Shape:White To Off-White SolidMolecular weight:485.56Deshydroxyethoxy ticagrelor
CAS:<p>Deshydroxyethoxy ticagrelor (AR-C124910) is a metabolite of Ticagrelor that exhibits antibacterial activity against MRSA and possesses antiplatelet effects.</p>Formula:C21H24F2N6O3SColor and Shape:SolidMolecular weight:478.515Deshydroxyethoxy Ticagrelor-d7
CAS:Controlled Product<p>Applications Labelled Deshydroxyethoxy Ticagrelor analog of Ticagrelor (T437700) an antiplatelet agent, and preventative in the treatment of heart attacks, myocardial infarction, and other pulmonary diseases.<br>References Zhang, H. et al.: Bioorg. Med. Chem. Lett., 22, 3598 (2012);<br></p>Formula:C21H17D7F2N6O3SColor and Shape:NeatMolecular weight:485.56Deshydroxyethoxy Ticagrelor
CAS:<p>Applications Deshydroxyethoxy Ticagrelor analog of Ticagrelor (T437700) an antiplatelet agent, and preventative in the treatment of heart attacks, myocardial infarction, and other pulmonary diseases.<br>References Zhang, H. et al.: Bioorg. Med. Chem. Lett., 22, 3598 (2012);<br></p>Formula:C21H24F2N6O3SColor and Shape:White To Off-WhiteMolecular weight:478.52Deshydroxyethoxy Ticagrelor
CAS:<p>Deshydroxyethoxy Ticagrelor is a metabolite that emerges as a derivative of the antiplatelet medication Ticagrelor. This compound originates from the biotransformation processes in the human body, where Ticagrelor undergoes metabolic conversion. As a metabolite, Deshydroxyethoxy Ticagrelor retains activity, contributing to the parent compound's overall therapeutic effect. The primary mode of action involves the reversible inhibition of the P2Y12 receptor on platelets, which plays a crucial role in the inhibition of platelet aggregation.<br><br>The applications of Deshydroxyethoxy Ticagrelor are primarily linked to the study of its pharmacokinetic and pharmacodynamic properties to understand better its contribution to Ticagrelor's efficacy and safety profile. Such insights can help refine dosing strategies and therapeutic regimens in clinical settings, enhancing antiplatelet therapy's precision, especially in managing acute coronary syndromes and preventing thrombotic vascular events. Understanding this metabolite is essential for developing next-generation antiplatelet agents and optimizing current treatment protocols.</p>Formula:C21H24F2N6O3SPurity:Min. 95%Color and Shape:PowderMolecular weight:478.52 g/mol
